Comparison of genome sequencing and clinical genotyping for pharmacogenes

Clinical Pharmacology and Therapeutics

Volumn , Issue , 2016, Pages 380-388

  Yang, W ^a   Wu, G ^a   Broeckel, U ^b   Smith, C A ^a   Turner, V ^a   Haidar, C E ^a   Wang, S ^a   Carter, R ^a   Karol, S E ^a   Neale, G ^a   Crews, K R ^a   Yang, J J ^a   Mullighan, C G ^a   Downing, J R ^a   Evans, W E ^a   Relling, M V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

ALLELE; ARTICLE; EXOME; GENE LOCUS; GENE SEQUENCE; GENETIC VARIATION; GENOTYPE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

EID: 84986625386     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.411     Document Type: Article

References (46)

1. Evans, W.E. et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19, 2293–2301 (2001).
2. Hicks, J.K. et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Ther. 92, 563–566 (2012).
3. Bell, G.C. et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. JAMIA 21, e93–99 (2014).
4. Hoffman, J.M. et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am. J. Med. Genet. C Semin. Med. Genet. 166C, 45–55 (2014).
5. Dunnenberger, H.M. et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55, 89–106 (2015).
6. Fernandez, C.A. et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin. Pharmacol. Ther. 92, 360–365 (2012).
7. Jackson, J.N. et al. A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure. Pharmacogenet. Genomics (2016); e-pub ahead of print.
8. KA W. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). . (2016).
9. Pirooznia, M. et al. Validation and assessment of variant calling pipelines for next-generation sequencing. Hum. Genomics. 8, 14 (2014).
10. Kingsmore, S.F. & Saunders, C.J. Deep sequencing of patient genomes for disease diagnosis: when will it become routine? Sci. Transl. Med. 3, 87ps23 (2011).
11. Tabor, H.K. et al. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. Am. J. Hum. Genet. 95, 183–193 (2014).
12. Biesecker, L.G. & Green, R.C. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 371, 1170 (2014).
13. Downing, J.R. et al. The Pediatric Cancer Genome Project. Nat. Genet. 44, 619–622 (2012).
14. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163 (2012).
15. Relling, M.V. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93, 324–325 (2013).
16. Relling, M.V. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin. Pharmacol. Ther. 96, 169–174 (2014).
17. Wilke, R.A. et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112–117 (2012).
18. Leckband, S.G. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94, 324–328 (2013).
19. Clancy, J.P. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin. Pharmacol. Ther. 95, 592–597 (2014).
20. Muir, A.J. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. Clin. Pharmacol. Ther. 95, 141–146 (2014).
21. Martin, M.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin. Pharmacol. Ther. 95, 499–500 (2014).
22. Gammal, R.S. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin. Pharmacol. Ther. (2015); e-pub ahead of print.
23. Birdwell, K.A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin. Pharmacol. Ther. 98, 19–24 (2015).
24. Hicks, J.K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin. Pharmacol. Ther. 98, 127–134 (2015).
25. Saito, Y. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin. Pharmacol. Ther. (2015); e-pub ahead of print.
26. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625–629 (2011).
27. Scott, S.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317–323 (2013).
28. Caudle, K.E. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94, 640–645 (2013).
29. Rasmussen-Torvik, L.J. et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin. Pharmacol. Ther. 96, 482–489 (2014).
30. Shukla, S.A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152–1158 (2015).
31. Fromer, M. et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am. J. Hum. Genet. 91, 597–607 (2012).
32. Beoris, M. Amos, Wilson J., Garces, J.A. & Lukowiak, A.A. CYP2D6 copy number distribution in the US population. Pharmacogenet. Genomics 26, 96–99 (2016).
33. Twist, G.P. et al. Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. Npj Genomic Med. 1, 15007 (2016).
34. Fang, H. et al. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 14, 564–572 (2014).
35. Te, H.S. et al. Donor liver uridine diphosphate (UDP)-glucuronosyltransferase-1A1 deficiency causing Gilbert’s syndrome in liver transplant recipients. Transplantation 69, 1882–1886 (2000).
36. Kishi, S. et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103, 67–72 (2004).
37. Ameyaw, M.M., Collie-Duguid, E.S., Powrie, R.H., Ofori-Adjei, D. & McLeod, H.L. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 8, 367–370 (1999).
38. Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310–3316 (2014).
39. Relling, M.V. & Evans, W.E. Pharmacogenomics in the clinic. Nature 526, 343–350 (2015).
40. Gordon, A.S. et al. PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet. Genomics (2016); e-pub ahead of print.
41. Gaedigk, A. et al. Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front. Pharmacol. 1, 121 (2010).
42. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383–391 (2001).
43. Numanagic, I. et al. Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data. Bioinformatics 31, i27–34 (2015).
44. Ramamoorthy, A. & Skaar, T.C. Gene copy number variations: it is important to determine which allele is affected. Pharmacogenomics 12, 299–301 (2011).
45. Ormond, K.E. et al. Challenges in the clinical application of whole-genome sequencing. Lancet 375, 1749–1751 (2010).
46. Chen, X. et al. CONSERTING: integrating copy-number analysis with structural-variation detection. Nat. Methods 12, 527–530 (2015).